Current status of the congenital myasthenic syndromes

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, and in the postsynaptic region of the motor endplate. The disease proteins identified to date include choline acetyltransferase (ChAT), the endplate species of acetylcholinesterase (AChE), β2-laminin, the acetylcholine receptor (AChR), rapsyn, plectin, Na v1.4, the muscle specific protein kinase (MuSK), agrin, downstream of tyrosine kinase 7 (Dok-7), and glutamine-fructose-6-phosphate transaminase 1 (GFPT1). Myasthenic syndromes associated with centronuclear myopathies were recently recognized. Analysis of properties of expressed mutant proteins contributed to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.

Original languageEnglish (US)
Pages (from-to)99-111
Number of pages13
JournalNeuromuscular Disorders
Volume22
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Congenital Myasthenic Syndromes
Plectin
Congenital Structural Myopathies
Agrin
Laminin Receptors
Motor Endplate
Choline O-Acetyltransferase
Muscle Proteins
Muscle Weakness
Presynaptic Terminals
Cholinergic Receptors
Mutant Proteins
Acetylcholinesterase
Transaminases
Glutamine
Basement Membrane
Protein-Tyrosine Kinases
Protein Kinases
Proteins
Safety

Keywords

  • Acetylcholine receptor
  • Agrin
  • Choline acetyltransferase
  • ColQ β2-laminin
  • Congenital myasthenic syndrome
  • Dok-7
  • EMG
  • Fetal akinesia syndrome
  • GFPT1
  • MuSK
  • Neuromuscular junction
  • Plectin
  • Rapsyn

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Cite this

Current status of the congenital myasthenic syndromes. / Engel, Andrew G.

In: Neuromuscular Disorders, Vol. 22, No. 2, 02.2012, p. 99-111.

Research output: Contribution to journalArticle

@article{8e856d49e9d241ca9d668c3480449b65,
title = "Current status of the congenital myasthenic syndromes",
abstract = "Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, and in the postsynaptic region of the motor endplate. The disease proteins identified to date include choline acetyltransferase (ChAT), the endplate species of acetylcholinesterase (AChE), β2-laminin, the acetylcholine receptor (AChR), rapsyn, plectin, Na v1.4, the muscle specific protein kinase (MuSK), agrin, downstream of tyrosine kinase 7 (Dok-7), and glutamine-fructose-6-phosphate transaminase 1 (GFPT1). Myasthenic syndromes associated with centronuclear myopathies were recently recognized. Analysis of properties of expressed mutant proteins contributed to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.",
keywords = "Acetylcholine receptor, Agrin, Choline acetyltransferase, ColQ β2-laminin, Congenital myasthenic syndrome, Dok-7, EMG, Fetal akinesia syndrome, GFPT1, MuSK, Neuromuscular junction, Plectin, Rapsyn",
author = "Engel, {Andrew G}",
year = "2012",
month = "2",
doi = "10.1016/j.nmd.2011.10.009",
language = "English (US)",
volume = "22",
pages = "99--111",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Current status of the congenital myasthenic syndromes

AU - Engel, Andrew G

PY - 2012/2

Y1 - 2012/2

N2 - Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, and in the postsynaptic region of the motor endplate. The disease proteins identified to date include choline acetyltransferase (ChAT), the endplate species of acetylcholinesterase (AChE), β2-laminin, the acetylcholine receptor (AChR), rapsyn, plectin, Na v1.4, the muscle specific protein kinase (MuSK), agrin, downstream of tyrosine kinase 7 (Dok-7), and glutamine-fructose-6-phosphate transaminase 1 (GFPT1). Myasthenic syndromes associated with centronuclear myopathies were recently recognized. Analysis of properties of expressed mutant proteins contributed to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.

AB - Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, and in the postsynaptic region of the motor endplate. The disease proteins identified to date include choline acetyltransferase (ChAT), the endplate species of acetylcholinesterase (AChE), β2-laminin, the acetylcholine receptor (AChR), rapsyn, plectin, Na v1.4, the muscle specific protein kinase (MuSK), agrin, downstream of tyrosine kinase 7 (Dok-7), and glutamine-fructose-6-phosphate transaminase 1 (GFPT1). Myasthenic syndromes associated with centronuclear myopathies were recently recognized. Analysis of properties of expressed mutant proteins contributed to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.

KW - Acetylcholine receptor

KW - Agrin

KW - Choline acetyltransferase

KW - ColQ β2-laminin

KW - Congenital myasthenic syndrome

KW - Dok-7

KW - EMG

KW - Fetal akinesia syndrome

KW - GFPT1

KW - MuSK

KW - Neuromuscular junction

KW - Plectin

KW - Rapsyn

UR - http://www.scopus.com/inward/record.url?scp=84856343171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856343171&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2011.10.009

DO - 10.1016/j.nmd.2011.10.009

M3 - Article

C2 - 22104196

AN - SCOPUS:84856343171

VL - 22

SP - 99

EP - 111

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 2

ER -